Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians

Main Article Content

M S Moolla
A Doruyter
B W Allwood

Abstract

-

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Moolla MS, Doruyter A, Allwood BW. Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians. Afr J Thoracic Crit Care Med [Internet]. 2023 Aug. 3 [cited 2024 Dec. 10];29(2):44-5. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/1231
Section
Editorials

How to Cite

1.
Moolla MS, Doruyter A, Allwood BW. Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians. Afr J Thoracic Crit Care Med [Internet]. 2023 Aug. 3 [cited 2024 Dec. 10];29(2):44-5. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/1231

References

Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J 2017;50(4). https://doi.org/10.1183/13993003.01209-2017

Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers 2017;3:17074. https://doi.org/10.1038/nrdp.2017.74

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205(9):e18-e47. https://doi. org/10.1164/rccm.202202-0399st

WoltersPJ,BlackwellTS,EickelbergO,etal.Timeforachange:isidiopathicpulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med 2018;6(2):154-160.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ, Group IPFCW. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018;51(5). https://doi.org/10.1183/13993003.00692-2018

The Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and n-acetylcysteine for pulmonary fibrosis. N Eng J Med 2012;366(21):1968-1977. https://doi.org/10.1056/nejmoa1113354

Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011;377(9779):1760- 1769. https://doi.org/10.1016/s0140-6736(11)60405-4

King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Eng J Med 2014;370(22):2083-2092. https://doi.org/10.1056/nejmoa1402582

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Eng J Med 2014;370(22):2071-2082. https://doi.org/10.1056/ nejmoa1402584

Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019;381(18):1718-1727.

Wuyts WA, Wijsenbeek M, Bondue B, et al. Idiopathic pulmonary fibrosis: Best practice in monitoring and managing a relentless fibrotic disease. Respiration 2020;99(1):73-82. https://doi.org/10.1159/000504763

Khan IY, Singer LG, de Perrot M, et al. Survival after lung transplantation in systemic sclerosis. A systematic review. Respir Med 2013;107(12):2081-2087. https://doi. org/10.1016/j.rmed.2013.09.015

Shane E, Silverberg SJ, Donovan D, et al. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease. Am J Med 1996;101(3):262-269. https:// doi.org/10.1016/s0002-9343(96)00155-6

Mora Cuesta VM, Iturbe Fernandez D, Gallardo Agromayor E, et al. Osteoporosis in lung transplant patients. European Resp J 2014;44(Suppl 58):P2456.

McQuiston A, Emtiazjoo A, Angel P, Machuca T, Christie J, Atkinson C. Set up for failure: pre-existing autoantibodies in lung transplant. Front Immunol 2021;12. https://doi.org/10.3389%2Ffimmu.2021.711102

Yazdani A, Singer LG, Strand V, Gelber AC, Williams L, Mittoo S. Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. J Heart Lung Transplant 2014;33(5):514-520. https://doi. org/10.1016/j.healun.2014.01.858

Most read articles by the same author(s)